The Association of the Epidermal Growth Factor Receptor (EGFR) Immunoexpression With Prognostic Parameters in Adenocarcinoma Patients Receiving Neoadjuvant Treatment

Basit Öğe Kaydı
dc.contributor.authorDemir, Derya
dc.contributor.authorParvizi, Murtaza
dc.contributor.authorPehlivanoglu, Burcin
dc.contributor.authorErgin, Erhan
dc.contributor.authorAyhan, Semin
dc.contributor.authorDoganavsargil, Basak
dc.date.accessioned2024-08-31T07:48:10Z
dc.date.available2024-08-31T07:48:10Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractThe epidermal growth factor receptor (EGFR) expression is considered to play an essential role in the pathogenesis of colorectal adenocarcinoma. This study assessed the expression and predictive/prognostic value of EGFR expression in pre -op biopsy and post -op resection specimens in patients receiving neoadjuvant radiotherapy/neoadjuvant chemoradiotherapy (NRT/NCRT). Thirty-four consecutive patients were included in this study. The association between the prognostic features and EGFR immunohistochemical expression was analyzed in pre- (n=34) and post -treatment (n=22) tissue samples in cases with available tissue blocks. Of 34, 23 (67.6%) were men. The median age was 60.50 +/- 10.69 (range, 31-84) years. EGFR expression was detected in 88.2% of biopsy specimens and in 91.2% of surgical specimens. There was only slight agreement between pre -op and post -op EGFR expression scores (kappa value 0.11). There was no significant correlation between pre -op and post -op EGFR expression scores (p>0.05). Although pre -op EGFR positivity and higher pre -op EGFR scores seemed to indicate a worse prognosis, this association between pre -op EGFR expression and overall survival (OS) or disease -specific survival (DSS) did not reach statistical significance (p>0.05). The only case with a post -op EGFR score of three who died of the disease experienced local recurrence and had distant metastasis. In conclusion, EGFR positivity in pre -op biopsy samples seems to be associated with shorter survival, and increased EGFR expression in post -treatment resection specimens predicts aggressive behavior in patients with rectal adenocarcinoma who received NRT/NCRT. However, due to the molecular heterogeneity, EGFR expression status should be evaluated in resection specimens rather than in pre -op biopsy samples for optimal prognosis prediction.en_US
dc.identifier.doi10.7759/cureus.56763
dc.identifier.issn2168-8184
dc.identifier.issue3en_US
dc.identifier.pmid38650801en_US
dc.identifier.urihttps://doi.org/10.7759/cureus.56763
dc.identifier.urihttps://hdl.handle.net/11454/104689
dc.identifier.volume16en_US
dc.identifier.wosWOS:001206997300020en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofCureus Journal of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240831_Uen_US
dc.subjectEgfren_US
dc.subjectAdenocarcinomaen_US
dc.subjectPrognosisen_US
dc.subjectNeoadjuvant Radiotherapyen_US
dc.subjectNeoadjuvant Chemoradiotherapyen_US
dc.titleThe Association of the Epidermal Growth Factor Receptor (EGFR) Immunoexpression With Prognostic Parameters in Adenocarcinoma Patients Receiving Neoadjuvant Treatmenten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu